ARTIFICIAL VITAL ORGANS AND MEDICAL BIONICS MARKET ANALYSIS

Market News

Global Artificial Vital Organs And Medical Bionics Market: Key Developments

On April 24, 2023, Picard Medical, Inc., the parent company of SynCardia Systems, LLC which is manufactures, sells, and markets the world’s first and only U.S. FDA approved and commercially available Total Artificial Heart mechanical heart replacement technology, announced that it has entered into a definitive business combination agreement with Altitude Acquisition Corp. a publicly traded special purpose acquisition company, that result in Picard Medical becoming a publicly listed company.

On March 29, 2023, BiVACOR, a preclinical artificial heart device company, announced US$18 Billion in funding led by Cormorant Asset Management and OneVentures is capital fund company, through the OneVentures Healthcare Fund III. The investments will fund the company’s continued research and development, fund the early feasibility first in human trials, and support hiring for key executive positions.

In November 2021, B. Braun, a medical and pharmaceutical device company in Germany, and REVA Medical, LLC., a leader in bioresorbable polymer technologies for vascular applications, announced the strategic partnership for the distribution of Fantom Encore, a bioresorbable scaffold for coronary interventions, manufactured with REVA's patented material Tyrocore. B. Braun started active distribution of the products in Germany and Switzerland.

In February 2020,  Ekso Bionics Holdings, Inc., a  developer of exoskeletons for medical and industrial use, announced a collaboration with Kindred Healthcare, LLC  healthcare services company that operated long-term acute-care hospitals and provides rehabilitation services across the United States. to pilot EksoNR— the most clinically used robotic exoskeleton, in their long-term acute care hospitals.

In June 2020, Asahi Kasei Medical is Pharma corporation, has completed its acquisition of Bionova Scientific, LLC, a provider of contract process development services and Good Medical Practice-compliant contract manufacturing services to biopharmaceutical companies as announced on April 19, 2022. The acquisition closed on May 31, 2022.

In February 2020,  Ekso Bionics Holdings, Inc., a  developer of exoskeletons for medical and industrial use, announced a collaboration with Kindred Healthcare, LLC  healthcare services company that operated long-term acute-care hospitals and provides rehabilitation services across the United States. to pilot EksoNR— the most clinically used robotic exoskeleton, in their long-term acute care hospitals.